CYP11A1 (D8F4F) Rabbit mAb #14217
- WB
- IP
- IF
Supporting Data
| REACTIVITY | H M R |
| SENSITIVITY | Endogenous |
| MW (kDa) | 50 |
| Source/Isotype | Rabbit IgG |
Application Key:
- WB-Western Blotting
- IP-Immunoprecipitation
- IF-Immunofluorescence
Species Cross-Reactivity Key:
- H-Human
- M-Mouse
- R-Rat
Product Information
Product Usage Information
| Application | Dilution |
|---|---|
| Western Blotting | 1:1000 |
| Immunoprecipitation | 1:50 |
| Immunofluorescence (Immunocytochemistry) | 1:400 - 1:800 |
Storage
Protocol
Specificity / Sensitivity
CYP11A1 (D8F4F) Rabbit mAb recognizes endogenous levels of total CYP11A1 protein.
Species Reactivity:
Human, Mouse, Rat
Source / Purification
Monoclonal antibody is produced by immunizing animals with a synthetic peptide corresponding to residues near the amino terminus of human CYP11A1 protein.
Background
In steroidogenic tissues, such as the adrenal cortex, testis, ovary, and placenta, all steroids are synthesized from the common precursor cholesterol. Two families of steroidogenic enzymes, cytochrome P450 hydroxylase enzymes (CYP) and hydroxysteroid dehydrogenases (HSD), catalyze the production of most steroids. There are six distinct steroid hydroxylases, which are cytochrome P450 enzymes encoded by the steroidogenic CYP gene family (1). The cytochrome P450scc (cholesterol side-chain cleavage enzyme) encoded by CYP11A1 catalyzes the first and rate-limiting step in steroidogenesis, conversion of cholesterol into pregnenolone (2).
CYP11A1, located in the inner membrane of mitochondria, cooperates with two coenzymes, ferredoxin and ferredoxin reductase, to carry out three successive oxidation-reduction reactions of cholesterol (3-5). In the adrenal cortex, testis, and ovary, CYP11A1 expression is regulated by the cAMP-PKA pathway (6), and the transcription factor SF1/NR5A1 has been shown to play a central role in mediating the cAMP signal on the CYP11A1 promoter within steroidogeneic cells of the adrenal cortex and gonads (7). Defects in CYP11A1 are the cause of adrenal insufficiency congenital with 46, XY sex reversal (AICSR), which is a rare disorder that can present as acute adrenal insufficiency in infancy or childhood (8,9).
Limited Uses
Except as otherwise expressly agreed in a writing signed by a legally authorized representative of CST, the following terms apply to Products provided by CST, its affiliates or its distributors. Any Customer's terms and conditions that are in addition to, or different from, those contained herein, unless separately accepted in writing by a legally authorized representative of CST, are rejected and are of no force or effect.
Products are labeled with For Research Use Only or a similar labeling statement and have not been approved, cleared, or licensed by the FDA or other regulatory foreign or domestic entity, for any purpose. Customer shall not use any Product for any diagnostic or therapeutic purpose, or otherwise in any manner that conflicts with its labeling statement. Products sold or licensed by CST are provided for Customer as the end-user and solely for research and development uses. Any use of Product for diagnostic, prophylactic or therapeutic purposes, or any purchase of Product for resale (alone or as a component) or other commercial purpose, requires a separate license from CST. Customer shall (a) not sell, license, loan, donate or otherwise transfer or make available any Product to any third party, whether alone or in combination with other materials, or use the Products to manufacture any commercial products, (b) not copy, modify, reverse engineer, decompile, disassemble or otherwise attempt to discover the underlying structure or technology of the Products, or use the Products for the purpose of developing any products or services that would compete with CST products or services, (c) not alter or remove from the Products any trademarks, trade names, logos, patent or copyright notices or markings, (d) use the Products solely in accordance with CST Product Terms of Sale and any applicable documentation, and (e) comply with any license, terms of service or similar agreement with respect to any third party products or services used by Customer in connection with the Products.